A randomized study of two interferon- beta treatments in relapsing-remitting multiple sclerosis

Neurology

Volumn 66, Issue 7, 2006, Pages 1056-1060

  Koch Henriksen, N ^a,b,j   Sorensen P S ^c   Christensen, T ^d   Frederiksen, J ^c   Ravnborg, M ^c   Jensen, K ^e   Heltberg, A ^f   Kristensen, O ^g   Stenager, E ^h   Petersen, T ^b   Hansen, T ⁱ  

^a Rigshospitalet   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

^e HILLERØD HOSPITAL   (Denmark)

^f ROSKILDE HOSPITAL   (Denmark)

^g ODENSE UNIVERSITY HOSPITAL   (Denmark)

^h Sønderborg Vejle and Esbjerg Hospitals ^*  (Denmark)

ⁱ UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^j AALBORG UNIVERSITY HOSPITAL   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; BETA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERFERON BETA-1B;

ADULT; ANTIBODY PRODUCTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENMARK; DEPRESSION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FLU LIKE SYNDROME; FREQUENCY ANALYSIS; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCORING SYSTEM; SKIN MANIFESTATION; STATISTICAL SIGNIFICANCE; ADOLESCENT; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; MIDDLE AGED; PROBABILITY;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROBABILITY;

EID: 33646117499     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000204018.52311.ec     Document Type: Article

References (8)

1. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002;59:1496-1506.
2. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-1460.
3. Koch-Henriksen N, Sorensen PS. The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group. Mult Scler 2000;6:172-175.
4. Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1997;49:358-363.
5. The IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
6. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
7. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsin-g-remitting multiple sclerosis. Lancet 2003;362:1184-91.
8. Ross C, Clemmesen KM, Svenson M, et al. Imnmnogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000;48:706-712.